XML 230 R41.htm IDEA: XBRL DOCUMENT v3.25.2

Business Segments (Tables)

12 Months Ended

Jun. 30, 2025

Business Segments

Schedule of information regarding reportable segments

​

​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​
For the Year Ended June 30	​	2025		​	2024		​	2023
Net sales		​			​			​
Animal Health	​	$	962,796	​	$	706,482	​	$	659,851
Mineral Nutrition	​		253,240	​		243,663	​		242,656
Performance Products	​		80,179	​		67,534	​		75,382
Total segments	​	$	1,296,215	​	$	1,017,679	​	$	977,889

​

​	​	​	​	​	​	​	​	​	​	​
For the Year Ended June 30		​	2025		​	2024		​	2023
Animal Health	​	​	​	​	​	​	​	​	​	​
Net sales			$	962,796	​	$	706,482	​	$	659,851
Cost of sales	​	​	​	607,069	​	​	428,683	​	​	399,016
Selling, general and administrative expenses (1)	​	​	​	182,310	​	​	162,009	​	​	152,410
Add: Depreciation and amortization	​	​	​	40,475	​	​	30,194	​	​	27,714
Add: Acquisition-related cost of goods sold (2)	​	​	​	5,679	​	​	521	​	​	—
Add: Phibro Forward income growth initiatives implementation costs - cost of goods sold (3)	​	​	​	3,798	​	​	—	​	​	—
Add: Phibro Forward income growth initiatives implementation costs - SG&A (3)	​	​	​	1,771	​	​	—	​	​	—
Subtract: Insurance proceeds (4)	​	​	​	(2,880)	​	​	(899)	​	​	—
Adjusted EBITDA	​	​	​	222,260	​	​	145,606	​	​	136,139
Mineral Nutrition	​	​	​	​	​	​	​	​	​	​
Net sales			​	253,240	​	​	243,663	​	​	242,656
Cost of sales	​	​	​	226,864	​	​	222,363	​	​	221,014
Selling, general and administrative expenses (1)	​	​	​	7,642	​	​	7,278	​	​	6,863
Add: Depreciation and amortization	​	​	​	2,102	​	​	2,427	​	​	2,638
Adjusted EBITDA	​	​	​	20,836	​	​	16,449	​	​	17,417
Performance Products	​	​	​	​	​	​	​	​	​	​
Net sales			​	80,179	​	​	67,534	​	​	75,382
Cost of sales	​	​	​	62,364	​	​	53,519	​	​	59,631
Selling, general and administrative expenses (1)	​	​	​	8,405	​	​	8,041	​	​	15,079
Add: Depreciation and amortization	​	​	​	1,137	​	​	1,688	​	​	1,780
Add: Environmental remediation costs (5)	​	​	​	—	​	​	—	​	​	6,894
Adjusted EBITDA	​	​	​	10,547	​	​	7,662	​	​	9,346
Adjusted EBITDA – Total segments	​	​	$	253,643	​	$	169,717	​	$	162,902
Reconciliation of Adjusted EBITDA to income before income taxes:	​	​	​	​	​	​	​	​	​	​
Less:	​	​	​	​	​	​	​	​	​	​
Interest expense, net	​	​		34,602	​		18,536	​		15,321
Depreciation and amortization – Total segments	​	​		43,714	​		34,309	​		32,132
Depreciation and amortization – Corporate	​	​		1,891	​		1,869	​		1,880
Corporate costs	​	​	​	69,959	​	​	58,480	​	​	50,149
Acquisition-related cost of goods sold	​	​		5,679	​		521	​		—
Acquisition-related transaction costs	​	​		13,322	​		6,405	​		—
Pension settlement cost	​	​	​	—	​	​	10,674	​	​	—
Brazil employment taxes	​	​	​	—	​	​	4,202	​	​	—
Stock-based compensation	​	​		717	​		475	​		—
Phibro Forward income growth initiatives implementation costs - cost of goods sold (3)	​	​	​	3,798	​	​	—	​	​	—
Phibro Forward income growth initiatives implementation costs - SG&A (3)	​	​	​	6,978	​	​	366	​	​	—
Insurance proceeds	​	​	​	(2,880)	​	​	(899)	​	​	—
Environmental remediation costs	​	​	​	—	​	​	—	​	​	6,894
Foreign currency losses, net	​	​		7,870	​		23,863	​		2,455
Income before income taxes	​	​	$	67,993	​	$	10,916	​	$	54,071

(1) Selling, general, and administrative expenses primarily include compensation-related expenses for employees not directly involved in the production and sale of inventory, rent expense, research and development costs, marketing expenses, and other general and administrative expenses.

(2) Represents cost of goods sold related to the stepped up value of inventory obtained in acquisitions.

(3) Phibro Forward is a company-wide initiative focused on unlocking additional areas of revenue growth and cost savings. For the year ended June 30, 2025, this included charges of $5.6 million related to the closure of an immaterial business within the Animal Health segment, of which $5.3 million was related to non-cash asset write-offs. $3.8 million of the non-cash asset write-offs was recorded within cost of goods sold and $1.5 million was recorded within selling, general, and administrative expenses. For the year ended June 30, 2025, charges related to Phibro Forward also include $5.2 million for Corporate consulting and other costs recorded within selling, general, and administrative expenses. For the year ended June 30, 2024, this included $0.4 million for Corporate consulting costs recorded within selling, general, and administrative expenses.

(4) Represents insurance settlement gains.

(5) Represents remediation costs mostly related to the definitive settlement agreement related to the Omega Chemical Corporation Superfund Site.

Schedule of geographic location of property, plant and equipment, net and operating lease ROU assets

​

​	​	​	​	​	​	​
As of June 30		2025			2024
Property, plant and equipment, net and operating lease ROU assets		​			​
United States	​	$	239,874	​	$	103,086
Israel	​		74,403	​		78,264
Brazil	​		34,504	​		32,266
Ireland	​	​	25,141	​	​	19,066
Other	​		22,107	​		8,222
​	​	$	396,029	​	$	240,904

X

- Definition

Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration